Yaser A. Diab

Dr. Yaser A. Diab

Hematology/Oncology, Children's National Hospital, Washington, District of Columbia, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2013 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
YDYaser A. Diab
Yaser A. Diab
EWEdward C. C. Wong
Edward C. C. Wong
NLNaomi L. C. Luban
Naomi L. C. Luban

3 November 2014 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
KFKatie R Forman
Katie R Forman
YDYaser A. Diab
Yaser A. Diab
EWEdward Cc Wong
Edward Cc Wong
SBStephen Baumgart
Stephen Baumgart
NLNaomi Lc Luban
Naomi Lc Luban
AMAn N Massaro
An N Massaro
Newborns with hypoxic ischemic encephalopathy (HIE) are at risk for coagulopathy due to systemic oxygen deprivation. Additionally, therapeutic hypothermia (TH) slows enzymatic activity of the coagulation cascade, leading to constitutive prolongation of routinely assessed coagulation studies. The level of laboratory abnormality that predicts bleeding is unclear, leading to varying transfusion therapy practices.

28 June 2015 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
NGN. A. Goldenberg
N. A. Goldenberg
TAT. Abshire
T. Abshire
PBP. J. Blatchford
P. J. Blatchford
LFL. Z. Fenton
L. Z. Fenton
JHJ. L. Halperin
J. L. Halperin
AZA. Zia
A. Zia
Background Randomized controlled trials (RCTs) on pediatric venous thromboembolism (VTE) treatment have been challenged by unsubstantiated design assumptions and/or poor accrual. Pilot/feasibility (P/F) studies are critical to future RCT success. Methods The Kids‐DOTT trial is a multicenter RCT investigating non‐inferiority of a 6‐week (shortened) versus 3‐month (conventional) duration of anticoagulation in patients aged < 21 years with provoked venous thrombosis. Primary efficacy and safety endpoints are symptomatic recurrent VTE at 1 year and anticoagulant‐related, clinically relevant bleeding. In the P/F phase, 100 participants were enrolled in an open, blinded‐endpoint, parallel‐cohort RCT design. Results No eligibility violations or randomization errors occurred. Of the enrolled patients, 69% were randomized, 3% missed the randomization window, and 28% were followed in prespecified observational cohorts for completely occlusive thrombosis or persistent antiphospholipid antibodies. Retention at 1 year was 82%. Interobserver agreement between local and blinded central determination of venous occlusion by imaging at 6 weeks after diagnosis was strong (k‐statistic = 0.75; 95% confidence interval [CI] 0.48–1.0). The primary efficacy and safety event rates were 3.3% (95% CI 0.3–11.5%) and 1.4% (95% CI 0.03–7.4%). Conclusions The P/F phase of the Kids‐DOTT trial has demonstrated the validity of vascular imaging findings of occlusion as a randomization criterion, and defined randomization, retention and endpoint rates to inform the fully powered RCT.

10 September 2012 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AGAndrea Guerin
Andrea Guerin
DSDimitri J Stavropoulos
Dimitri J Stavropoulos
YDYaser A. Diab
Yaser A. Diab
SCSébastien Chénier
Sébastien Chénier
HCHilary Christensen
Hilary Christensen
DCDavid Chitayat
David Chitayat

1 February 2020 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
AZApril Zhang
April Zhang
SDSabine Duchatelet
Sabine Duchatelet
NLNikita Lakdawala
Nikita Lakdawala
RTRichard L. Tower
Richard L. Tower
CDCarrie Diamond
Carrie Diamond
AHAlain HOVNANIAN
Alain HOVNANIAN
Importance Olmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available. Objective To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlotinib among patients with Olmsted syndrome. Design, Setting, and Participants This case series focused on 4 children with treatment-refractory Olmsted syndrome. These children received treatments (initiated in 2017 and 2018) at the outpatient dermatology clinic at the Children’s Hospital of Wisconsin in Milwaukee, Wisconsin; Children’s National Hospital in Washington, DC; and Hospital Infantil Pequeno Príncipe, Curitiba in Paraná, Brazil. Exposures Immunohistochemical analyses for mTOR and EGFR activation were performed on skin biopsy specimens from 2 patients. Oral sirolimus was administered to these 2 patients at a dosage of 0.8 mg/m2twice daily, titrated to a goal trough whole-blood concentration of 10 to 15 ng/mL. Erlotinib was administered to all 4 patients at a dosage of 2 mg/kg/d. Main Outcomes and Measures Clinical responses were assessed with visual analog scales for pruritus and pain and/or the Children’s Dermatology Life Quality Index. Adverse effects were monitored throughout treatment. Results Four patients (mean [SD] age, 7 [6] years; 2 boys and 2 girls) were analyzed. Lesional skin immunostaining showed increased phosphorylated ribosomal protein S6 (RPS6) and phosphorylated EGFR staining in the epidermis, indicating enhanced mTOR and EGFR signaling activation. Patients 1 and 2 were initially treated with sirolimus, displaying substantial clinical improvement in erythema and periorificial hyperkeratosis afterward. When switched to erlotinib, these patients showed substantial palmoplantar keratoderma (PPK) improvement. Patients 3 and 4 were treated with erlotinib only and later showed rapid and near complete resolution of PPK and substantial improvement in Children’s Dermatology Life Quality Index scores. All 4 patients had sustained improvements in pruritus and pain. No severe adverse effects were reported. Conclusions and Relevance This study’s findings suggest that the EGFR-mTOR cascade may play a substantial role in the pathophysiological process of Olmsted syndrome and may serve as a major therapeutic target. Oral sirolimus and erlotinib may be a promising, life-altering treatment for pediatric patients with Olmsted syndrome.

1 October 2011 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
LBLeonardo R Brandão
Leonardo R Brandão
VLVeerle Labarque
Veerle Labarque
YDYaser A. Diab
Yaser A. Diab
SWSuzan Williams
Suzan Williams
DMDavid E. Manson
David E. Manson
Pulmonary embolism (PE) has long been described in children. Nevertheless, most of the algorithms applied to patients within this age range, from diagnosis to therapy, have been adapted from adult protocols. This article reviews the progresses that occurred to PE in children placing them in historical perspective with the key events relevant to PE in adults. A brief summary of the initial reports encountered in the pediatric literature followed by key conclusions drawn from national database reports characterizing its epidemiology in children is highlighted. Additionally, a section with the diagnostic tools pertaining to children is included. Closing remarks encompass commentaries related to therapy and outcomes, reflecting on current knowledge gaps related to PE in children.